Adecatumumab
Based on 1 Customer Validation
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.54%
- CAS No.: 503605-66-1
- 분자량:147.52 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
EpCAM/TROP1/CD326
In Vitro
Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells[2].
Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)[2]
-
Dosage:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
-
Administration:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
-
Result:Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice.
Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference.
In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5×106 HT-29 cells labeling Adecatumumab (HY-P99278, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS No. 503605-66-1
-
Accession P16422
-
Synonyms MT 201; Anti-Human EPCAM Recombinant Antibody
-
분자량 147.52 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.54%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
순도&문서
References
[1]. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. [Content Brief]
[2]. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)